Prevalence and Clinicopathological Characteristics of Islet Amyloid in Chinese Patients with Type 2 Diabetes

Diabetes

Volumn 52, Issue 11, 2003, Pages 2759-2766

  Zhao, Hai Lu ^a   Lai, Fernand M M ^a   Tong, Peter C Y ^a   Zhong, Ding Rong ^b   Yang, Di ^c   Tomlinson, Brian ^a   Chan, Juliana C N ^a  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^b CHINESE PLA GENERAL HOSPITAL   (China)

^c PekingUnion Hospital   (China)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLIN; CONGO RED; GLUCOSE;

ADULT; AGED; ARTERIOSCLEROSIS; ARTICLE; AUTOPSY; BLOOD PRESSURE REGULATION; BODY MASS; CELL INFILTRATION; CHINESE; CONTROLLED STUDY; DISEASE EXACERBATION; FEMALE; FIBROSIS; GLUCOSE BLOOD LEVEL; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMAGE ANALYSIS; INSULIN RESISTANCE; MALE; METABOLIC REGULATION; NON INSULIN DEPENDENT DIABETES MELLITUS; PANCREAS INSUFFICIENCY; PANCREAS ISLET BETA CELL; PREVALENCE; PRIORITY JOURNAL;

ADULT; AGED; AMYLOID; ARTERIOSCLEROSIS; AUTOPSY; BIOLOGICAL MARKERS; BLOOD PRESSURE; BODY MASS INDEX; CHINA; CHOLESTEROL; CHOLESTEROL, HDL; CHOLESTEROL, LDL; DIABETES MELLITUS, TYPE 2; FEMALE; HONG KONG; HUMANS; ISLETS OF LANGERHANS; MALE; MEDICAL RECORDS; PANCREAS; REFERENCE VALUES; RETROSPECTIVE STUDIES;

EID: 0242332129     PISSN: 00121797     EISSN: None     Source Type: Journal    
DOI: 10.2337/diabetes.52.11.2759     Document Type: Article

References (41)

1. Weyer C, Bogardus C, Mott DM, Pratley RE: The natural history of insulin secretory dysfunction and insulin resistance in the pathogenesis of type 2 diabetes mellitus. J Clin Invest 104:787-794, 1999
2. Ferrannini E: Insulin resistance versus insulin deficiency in non-insulin-dependent diabetes mellitus: problems and prospects. Endocr Rev 19:477-490, 1998
3. Taylor SI, Accili D, Imai Y: Insulin resistance or insulin deficiency. Which is the primary cause of NIDDM? Diabetes 43:735-740, 1994
4. Hoppener JW, Ahren B, Lips CJ: Islet amyloid and type 2 diabetes mellitus. N Engl J Med 343:411-419, 2000
5. Kahn SE, Andrikopoulos S, Verchere CB: Islet amyloid: a long-recognized but underappreciated pathological feature of type 2 diabetes. Diabetes 48:241-253, 1999
6. de Koning EJ, Bodkin NL, Hansen BC, Clark A: Diabetes mellitus in Macaca mulatta monkeys is characterised by islet amyloidosis and reduction in beta-cell population. Diabetologia 36:378-384, 1993
7. Clark A, Jones LC, de Koning E, Hansen BC, Matthews DR: Decreased insulin secretion in type 2 diabetes: a problem of cellular mass or function? Diabetes 50 (Suppl. 1):S169-S171, 2001
8. Maloy AL, Longnecker DS, Greenberg ER: The relation of islet amyloid to the clinical type of diabetes. Hum Pathol 12:917-922, 1981
9. Westermark P: Amyloid and polypeptide hormones. What is their interrelationship? Amyloid 1:47-60, 1994
10. Clark A, Charge SB, Badman MK, de Koning EJ: Islet amyloid in type 2 (non-insulin-dependent) diabetes. APMIS 104:12-18, 1996
11. Clark A, Wells CA, Buley ID, Cruickshank JK, Vanhegan RI, Matthews DR, Cooper GJ, Holman RR, Turner RC: Islet amyloid, increased A-cells, reduced B-cells and exocrine fibrosis: quantitative changes in the pancreas in type 2 diabetes. Diabetes Res 9:151-159, 1988
12. Bell ET: Hyalinization of the islets of Langerhans in diabetes mellitus. Diabetes 1:341-344, 1952
13. Westermark P, Engstrom U, Johnson KH, Westermark GT, Betsholtz C: Islet amyloid polypeptide: pinpointing amino acid residues linked to amyloid fibril formation. Proc Natl Acad Sci U S A 87:5036-5040, 1990
14. Clark A, Saad MF, Nezzer T, Uren C, Knowler WC, Bennett PH, Turner RC: Islet amyloid polypeptide in diabetic and non-diabetic Pima Indians. Diabetologia 33:285-289, 1990
15. Vishwanathan KA, Bazaz-Malik G, Dandekar J, Vaishnava H: A qualitative and quantitative histological study of the islets of Langerhans in diabetes mellitus. Indian J Med Sci 26:807-812, 1972
16. Saito K, Yaginuma N, Takahashi T: Differential volumetry of A, B and D cells in the pancreatic islets of diabetic and nondiabetic subjects. Tohoku J Exp Med 129:273-283, 1979
17. Ohsawa H, Kanatsuka A, Mizuno Y, Tokuyama Y, Takada K, Mikata A, Makino H, Yoshida S: Islet amyloid polypeptide-derived amyloid deposition increases along with the duration of type 2 diabetes mellitus. Diabetes Res Clin Pract 15:17-21, 1992
18. Rahier J, Goebbels RM, Henquin JC: Cellular composition of the human diabetic pancreas. Diabetologia 24:366-371, 1983
19. Pancreatic abnormalities in type 2 diabetes mellitus (Editorial). Lancet ii:1497-1498, 1987
20. Clark A, de Koning EJ, Hattersley AT, Hansen BC, Yajnik CS, Poulton J: Pancreatic pathology in non-insulin dependent diabetes (NIDDM). Diabetes Res Clin Pract 28:S39-S47, 1995
21. International Obesity Task Forces: The Asia-Pacific Prospective: Redefining Obesity and Its Treatment. Sydney, Health Communications Australia, 2000, p. 15-21
22. Rocken C, Linke RP, Saeger W: Immunohistology of islet amyloid polypeptide in diabetes mellitus: semi-quantitative studies in a post-mortem series. Virchows Arch 421:339-344, 1992
23. O'Brien TD, Butler AE, Roche PC, Johnson KH, Butler PC: Islet amyloid polypeptide in human insulinomas: evidence for intracellular amyloidogenesis. Diabetes 43:329-336, 1994
24. Cooper GJ, Willis AC, Clark A, Turner RC, Sim RB, Reid KB: Purification and characterization of a peptide from amyloid-rich pancreases of type 2 diabetic patients. Proc Natl Acad Sci U S A 84:8628-8632, 1987
25. Puchtler H, Sweat F, Levine M: On the binding of Congo red by amyloid. J Histochem Cytochem 10:355-364, 1962
26. Kelenyi G: Thioflavin S fluorescent and Congo red anisotropic stainings in the histologic demonstration of amyloid. Acta Neuropathol 7:336-348, 1967
27. Hoppener JW, Oosterwijk C, Nieuwenhuis MG, Posthuma G, Thijssen JH, Vroom TM, Ahren B, Lips CJ: Extensive islet amyloid formation is induced by development of Type II diabetes mellitus and contributes to its progression: pathogenesis of diabetes in a mouse model. Diabetologia 42:427-434, 1999
28. Hoppener JW, Nieuwenhuis MG, Vroom TM, Ahren B, Lips CJ: Role of islet amyloid in type 2 diabetes mellitus: consequence or cause? Mol Cell Endocrinol 197:205-212, 2002
29. Butler AE, Janson J, Bonner-Weir S, Ritzel R, Rizza RA, Butler PC: Beta-cell deficit and increased beta-cell apoptosis in humans with type 2 diabetes. Diabetes 52:102-110, 2003
30. Erlich JC, Ratner IM: Amyloidosis of the islets of Langerhans: a restudy of islet hyaline in diabetic and nondiabetic individuals. Am J Pathol 38:49-59, 1961
31. Westermark P, Wilander E: The influence of amyloid deposits on the islet volume in maturity onset diabetes mellitus. Diabetologia 15:417-421, 1978
32. Lorenzo A, Razzaboni B, Weir GC, Yankner BA: Pancreatic islet cell toxicity of amylin associated with type-2 diabetes mellitus. Nature 368:756-760, 1994
33. Janson J, Ashley RH, Harrison D, McIntyre S, Butler PC: The mechanism of islet amyloid polypeptide toxicity is membrane disruption by intermediate-sized toxic amyloid particles. Diabetes 48:491-498, 1999
34. Janson J, Soeller WC, Roche PC, Nelson RT, Torchia AJ, Kreutter DK, Butler PC: Spontaneous diabetes mellitus in transgenic mice expressing human islet amyloid polypeptide. Proc Natl Acad Sci U S A 93:7283-7288, 1996
35. Butler PC: Islet amyloid and its potential role in the pathogenesis of type 2 diabetes mellitus. In Diabetes Mellitus: A Fundamental and Clinical Text. 2nd ed. LeRoith D, Taylor SI, Olefsky JM, Eds. Philadelphia, Lippincott Williams & Wilkins, 2000, p. 141-146
36. Janciauskiene S, Ahren B: Fibrillar islet amyloid polypeptide differentially affects oxidative mechanisms and lipoprotein uptake in correlation with cytotoxicity in two insulin-producing cell lines. Biochem Biophys Res Commun 267:619-625, 2000
37. Pieber TR, Roitelman J, Lee Y, Luskey KL, Stein DT: Direct plasma radioimmunoassay for rat amylin-(1-37): concentrations with acquired and genetic obesity. Am J Physiol 267:E156-E164, 1994
38. Soeller WC, Janson J, Hart SE, Parker JC, Carty MD, Stevenson RW, Kreutter DK, Butler PC: Islet amyloid-associated diabetes in obese avy/a mice expressing human islet amyloid polypeptide. Diabetes 47:743-750, 1998
39. Kautzky-Willer A, Thomaseth K, Pacini G, Clodi M, Ludvik B, Streli C, Waldhausl W, Prager R: Role of islet amyloid polypeptide secretion in insulin-resistant humans. Diabetologia 37:188-194, 1994
40. Kailasam MT, Parmer RJ, Tyrell EA, Henry RR, O'Connor DT: Circulating amylin in human essential hypertension: heritability and early increase in individuals at genetic risk. J Hypertens 18:1611-1620, 2000
41. Kauppila LI, Hekali P, Penttila A: Postmortem pancreatic angiography in 45 subjects with non-insulin-dependent diabetes mellitus and 51 controls. Pancreas 16:60-65, 1998